Onkolojik Tedaviye Bağlı Aritmilere Genel Yaklaşım

Yeh ET, Bickford CL. Cardiovascularcomplications of cancertherapy: incidence, pathogenesis, diagnosis, andmanagement. J AmCollCardiol. 2009 Jun 16;53(24):2231-47.

Tamargo J, Caballero R, Delpón E. Cancerchemotherapyandcardiacarrhythmias: a review. Drug Saf. 2015 Feb;38(2):129-52.

Viganego F, Singh R, Fradley MG. ArrhythmiasandOtherElectrophysiologyIssues in CancerPatientsReceivingChemotherapyorRadiation. CurrCardiolRep. 2016 Jun;18(6):52.

Buza V, Rajagopalan B, Curtis AB. CancerTreatment-InducedArrhythmias: Focus on ChemotherapyandTargetedTherapies. CircArrhythmElectrophysiol. 2017 Aug;10(8):e005443.

Guglin M, Aljayeh M, Saiyad S, et al. Introducing a newentity: chemotherapy-inducedarrhythmia. Europace. 2009 Dec;11(12):1579-86.

Senkus E, Jassem J. Cardiovasculareffects of systemiccancertreatment. CancerTreatRev. 2011 Jun;37(4):300-11.

Suter TM, Ewer MS. Cancerdrugsandtheheart: importanceandmanagement. EurHeart J. 2013 Apr;34(15):1102-11.

Velagapudi P, Turagam MK, Kocheril AG. Atrialfibrillation in cancerpatients: an underrecognizedcondition. South Med J. 2011 Sep;104(9):667-8.

Lainscak M, Dagres N, Filippatos GS, et al. Atrialfibrillation in chronicnon-cardiacdisease: where do westand? Int J Cardiol. 2008 Aug 29;128(3):311-5.

Force T, Kolaja KL. Cardiotoxicity of kinaseinhibitors: thepredictionandtranslation of preclinicalmodelstoclinicaloutcomes. NatRevDrugDiscov. 2011 Feb;10(2):111-26.

Ostenfeld EB, Erichsen R, Pedersen L, et al. Atrialfibrillation as a marker of occultcancer. PLoSOne. 2014 Aug 13;9(8):e102861.

Strevel EL, Ing DJ, Siu LL. Molecularlytargetedoncologytherapeuticsandprolongation of the QT interval. J ClinOncol. 2007 Aug 1;25(22):3362-71.

Curtis MJ, Hancox JC, Farkas A, et al. TheLambethConventions (II): guidelinesforthestudy of animalandhumanventricularandsupraventriculararrhythmias. PharmacolTher. 2013 Aug;139(2):213-48.

Schwartz PJ, Wolf S. QT intervalprolongation as predictor of suddendeath in patientswithmyocardialinfarction. Circulation. 1978 Jun;57(6):1074-7.

Li EC, Esterly JS, Pohl S, et al. Drug-induced QT-intervalprolongation: considerationsforclinicians. Pharmacotherapy. 2010 Jul;30(7):684-701.

Yeh ET. Onco-cardiology: the time has come. TexHeartInst J. 2011;38(3):246-7.

Desai M, Li L, Desta Z, et al. Variability of heart rate correctionmethodsforthe QT interval. Br J ClinPharmacol. 2003 Jun;55(6):511-7.

GuidanceforIndustry: E14 Clinical Evaluation of QT/QTcIntervalProlongationandProarrhythmicPotentialforNon-AntiarrhythmicDrugs. Available at: http://www.fda.gov/downloads/Regulatory/Information/Guidances/ucm129357.pdf.Accessed May 13, 2013.

NationalCancerInstitute. CommonTerminologyCriteriaforAdverseEvents v 4.0. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 – 06 14_QuickReference_8.5x11.pdf.Accessed May 13, 2013.

Menna P, Salvatorelli E, Minotti G. Cancerdrugsand QT prolongation: weighing risk againstbenefit. ExpertOpinDrug Saf. 2017 Oct;16(10):1099-1102.

Fradley MG, Moslehi J. QT ProlongationandOncologyDrug Development. CardElectrophysiolClin. 2015 Jun;7(2):341-55.

Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenictrioxide on QT interval in patientswithadvancedmalignancies. J ClinOncol. 2003 Oct 1;21(19):3609-15.

Roboz GJ, Ritchie EK, Carlin RF, et al. Prevalence, management, andclinicalconsequences of QT intervalprolongationduringtreatmentwitharsenictrioxide. J ClinOncol. 2014 Nov 20;32(33):3723-8.

Lu Z, Wu CY, Jiang YP, et al. Suppression of phosphoinositide 3-kinase signalingandalteration of multipleioncurrents in drug-inducedlong QT syndrome. SciTranslMed. 2012 Apr 25;4(131):131ra50.

Porta-Sánchez A, Gilbert C, Spears D, et al. Incidence, Diagnosis, and Management of QT ProlongationInducedbyCancerTherapies: A SystematicReview. J AmHeartAssoc. 2017 Dec 7;6(12):e007724.

Zang J, Wu S, Tang L, et al. Incidenceand risk of QTcintervalprolongationamongcancerpatientstreatedwithvandetanib: a systematicreviewand meta-analysis. PLoSOne. 2012;7(2):e30353.

Thill M, Schmidt M. Management of adverseeventsduringcyclin-dependentkinase 4/6 (CDK4/6) inhibitor-basedtreatment in breastcancer. TherAdvMedOncol. 2018 Sep3;10:1758835918793326.

Johnson DB, Balko JM, Compton ML, et al. FulminantMyocarditiswith Combination ImmuneCheckpointBlockade. N Engl J Med. 2016 Nov 3;375(18):1749-1755.

Mir H, Alhussein M, Alrashidi S, et al. CardiacComplicationsAssociatedWithCheckpointInhibition: A SystematicReview of theLiterature in an ImportantEmergingArea. Can J Cardiol. 2018 Aug;34(8):1059-1068.

Woosley RL, Heise CW, Romero KA. Qtdrugslist. Retrievedfrom: https:// www.crediblemeds.org/. AccessedOctober 10, 2017.

Weissler-Snir A, Gollob MH, Chauhan V, et al. Evaluation of Prolonged QT Interval: StructuralHeartDiseaseMimickingLong QT Syndrome. PacingClinElectrophysiol. 2017 Apr;40(4):417-424.

Zamorano JL, Lancellotti P, RodriguezMuñoz D, et al. 2016 ESC PositionPaper on cancertreatmentsandcardiovasculartoxicitydevelopedundertheauspices of the ESC CommitteeforPracticeGuidelines: TheTask Force forcancertreatmentsandcardiovasculartoxicity of theEuropeanSociety of Cardiology (ESC). EurHeart J. 2016 Sep 21;37(36):2768-2801.